Acquista crypto Mercati Spot FuturesGOLD Earn Centro eventi

Altro

Citybuzz

Citybuzz is a vibrant local lifestyle and news media outlet. While primarily reporting on community events and entertainment it also actively covers business innovation and tech trends acting as a window connecting local audiences with modern digital lifestyle trends.

Articoli di Citybuzz

Trevino Law Celebrates 651 Five-Star Reviews in Texas and Colorado

Trevino Law, led by veteran attorney Jaime Trevino, has reached a milestone 651 five-star Google reviews across its Texas and Colorado markets. With 16

2026/04/18

Precision Oncology Shifts Focus to Combination Therapies as Industry Addresses Treatment Resistance

Lixte Biotechnology advances first-in-class PP2A inhibitor LB-100 in combination cancer therapy trials. Learn how precision oncology is shifting toward multi-drug

2026/04/18

UGI Utilities Recognized as ‘Easiest to Do Business With’ Utility in 2026 Study

UGI Utilities earns "Easiest to Do Business With" utility recognition in 2026 study for outstanding billing and payment customer experiences. Learn more about this

2026/04/18

Soligenix Reports Progress in CTCL Treatment Research With Interim Analysis and Comparative Study Results

Soligenix reports positive phase 3 data for HyBryte therapy in CTCL treatment, showing promising results compared to existing options. Read the latest clinical

2026/04/18

Rail Vision’s AI-Powered Systems Address Growing Railway Safety Demands

Rail Vision's AI-powered electro-optical sensors enhance railway safety with real-time obstacle detection and situational awareness technology for complex rail

2026/04/18

LIXTE Biotechnology’s LB-100 Represents Novel Approach to Enhancing Cancer Therapies

LIXTE Biotechnology's LB-100 enhances cancer therapy effectiveness through PP2A inhibition. Clinical trials target ovarian, colon cancers & sarcoma with novel activation

2026/04/18

Cardio Diagnostics Leverages AI and Epigenetics for Precision Cardiovascular Medicine

Cardio Diagnostics uses AI, genetics & epigenetics to revolutionize cardiovascular disease prevention & management. Learn how their precision medicine approach

2026/04/18

Suntex Enterprises Completes Restructuring, Announces Dividend Plan and Growth Strategy

Suntex Enterprises (SNTX) files annual statements, announces dividend plans, and targets $100M revenue. Learn about its debt-free restructuring and growth strategy

2026/04/18

European Commission Grants Orphan Drug Designation to Soligenix’s SGX945 for Behçet’s Disease Treatment

Soligenix receives EU orphan drug designation for SGX945 in Behçet's disease treatment, validating its dusquetide-based therapy and strengthening its rare disease

2026/04/18

Precision Oncology Shifts to Combination Strategies as New Therapies Target Treatment Enhancement

Lixte Biotechnology's LB-100 enhances cancer treatment combos in precision oncology shift. First-in-class PP2A inhibitor boosts chemo & immunotherapy effectiveness

2026/04/17

Prezzi delle criptovalute

Bitcoin

BTC

$77,078.86

$77,078.86$77,078.86

-0.90%

Ethereum

ETH

$2,409.51

$2,409.51$2,409.51

-1.31%

Solana

SOL

$88.41

$88.41$88.41

-1.71%

XRP

$1.4699

$1.4699$1.4699

-1.10%

USDCoin

USDC

$0.9996

$0.9996$0.9996

+0.02%

Citybuzz

Articoli di Citybuzz

Trevino Law Celebrates 651 Five-Star Reviews in Texas and Colorado

Precision Oncology Shifts Focus to Combination Therapies as Industry Addresses Treatment Resistance

UGI Utilities Recognized as ‘Easiest to Do Business With’ Utility in 2026 Study

Soligenix Reports Progress in CTCL Treatment Research With Interim Analysis and Comparative Study Results

Rail Vision’s AI-Powered Systems Address Growing Railway Safety Demands

LIXTE Biotechnology’s LB-100 Represents Novel Approach to Enhancing Cancer Therapies

Cardio Diagnostics Leverages AI and Epigenetics for Precision Cardiovascular Medicine

Suntex Enterprises Completes Restructuring, Announces Dividend Plan and Growth Strategy

European Commission Grants Orphan Drug Designation to Soligenix’s SGX945 for Behçet’s Disease Treatment

Precision Oncology Shifts to Combination Strategies as New Therapies Target Treatment Enhancement

Selezioni dell'autore

Olenox Industries Stockholders Approve Key Corporate Actions, Reject Merger Proposal

UGI Utilities Recognized as ‘Easiest to Do Business With’ Utility in 2026 Study

Chisos Boot Company Elevates Handcrafted Cowboy Boots with Uncompromising Materials and Proprietary Comfort Technology

Trevino Law Celebrates 651 Five-Star Reviews in Texas and Colorado

Precision Oncology Shifts Focus to Combination Therapies as Industry Addresses Treatment Resistance

Prezzi delle criptovalute